Component doses and the composition of the 80 mg vial

In plain English

This page covers how the KLOW blend's four components were dosed in published research, and what the standard 80 mg vial actually contains. It does not recommend any dose for human use — no validated human dosing exists for the blend or for any of its four components in this context. Everything here is research context: the doses animals or cells were given in published studies, and the vial composition that appears across independent compounders.

The single most important dosing fact about KLOW peptide is this: the four peptides clear at markedly different rates. KPV and GHK-Cu are tripeptides that clear fast; BPC-157 clears more slowly; the TB-500 fragment behaves differently from native thymosin beta-4. Putting all four in one vial creates a pharmacokinetic mismatch — the window in which all four are simultaneously present at any meaningful level may be narrow. This is not a contraindication; it is an honest gap in what we know about how a co-formulated dose actually behaves. No pharmacokinetic study has characterized the blend.

KLOW peptide dosage: the canonical 80 mg vial composition

The most widely listed research-vial composition across independent compounders is an 80 mg total vial divided as follows:

GHK-Cu dominates the vial by mass — approximately 62.5% — because its topical cosmetic literature involves milligram-range quantities and its role as a copper-delivery agent for lysyl oxidase crosslinking requires a meaningful copper load. The three smaller components are each at the lower end of the milligram range, closer to the doses used in animal studies on a per-kilogram basis.

This is the composition of a standard research vial. It is not the output of a clinical dose-optimization study — no such study exists for the blend.

KLOW dosage: component-level research doses

Each component was dosed differently across its research history. These figures are from the studies cited on the KLOW research page and represent doses administered to specific species by specific routes — not human dose recommendations.

TB-500 / thymosin beta-4. The rat full-thickness wound model used topical application and intraperitoneal injection of thymosin beta-4; migration assays showed activity at as little as 10 picograms ^[1]. The TB-500 fragment is the synthetic heptapeptide form; the wound data cited are for the full-length 43-amino-acid native protein.

BPC-157. In the rat Achilles tendon transection model, doses of 10 micrograms, 10 nanograms and 10 picograms per rat via intraperitoneal injection once daily were tested ^[2]. The 2025 human IV safety pilot administered 10 mg on day one and 20 mg on day two in intravenous infusion ^[6] — the only human-dose reference in the BPC-157 literature and explicitly not an efficacy trial.

KPV. In cell-culture models, nanomolar concentrations (around 10 nM) inhibited NF-kappaB and MAP-kinase signaling ^[3]. In mouse colitis models, 100 micromolar KPV in drinking water was the oral dose studied. The PepT1 transporter Km is approximately 160 micromolar, relevant to oral-delivery dosing considerations.

GHK-Cu. In vitro transcriptomic and fibroblast studies used 1-10 nanomolar concentrations ^[5]. Topical clinical studies used formulated cosmetic products — the specific concentration varied. Liposomal delivery research used 0.5 mg per cubic centimeter in 25 mg per cubic centimeter lipid formulations ^[11].

KLOW peptide dosage and frequency: the pharmacokinetic mismatch

A pharmacokinetic mismatch is inherent to the KLOW blend. The four components have markedly different reported half-lives — BPC-157 has a short elimination half-life (under approximately 30 minutes in formal PK study data), and the tripeptides KPV and GHK-Cu likely clear even faster due to their small molecular size. The TB-500 heptapeptide fragment's PK has not been formally characterized; native thymosin beta-4 has a different profile.

This means that a single co-formulated dose of all four cannot maintain all four components at matched exposures simultaneously. Whichever component clears fastest will be at low or negligible levels before the slower-clearing component has even reached half of its exposure. This is not a reason to assume the blend fails; it is a gap in the combination hypothesis that no published study has addressed.

Research-vial handling: the lyophilized blend is typically reconstituted with bacteriostatic water and refrigerated. The copper(II) ion in GHK-Cu can participate in redox chemistry — a theoretical compatibility consideration when co-dissolved with the other peptides in one vial that has not been formally characterized for this mixture.

For routes of administration: the component literature includes subcutaneous injection (the most common research-handling route), topical application for GHK-Cu, oral and targeted-delivery for KPV and BPC-157 in gut-focused studies, and intra-articular injection for BPC-157 in joint models. The blend as co-formulated is typically handled via subcutaneous injection in research contexts.

Routes studied and delivery considerations

The KLOW components have been studied via multiple routes in the published literature:

• Subcutaneous injection — the most common research-handling route for TB-500 and BPC-157 in rodent models.
• Intraperitoneal injection — used in thymosin beta-4 wound models ^[1] and BPC-157 tendon studies ^[2].
• Topical application — GHK-Cu in cosmetic/dermatology studies ^[4]; thymosin beta-4 in the wound model ^[1].
• Oral / drinking water — KPV in mouse colitis models ^[3]; BPC-157 in GI-protection studies.
• Intravenous infusion — BPC-157 in the 2025 human safety pilot ^[6].

No route has been validated for the four-peptide KLOW blend at any dose. The subcutaneous route is the most commonly referenced in research-use-community discussions of the blend, but this is not based on a formal pharmacokinetic study of the co-formulated product.